Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC).
about
Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue TargetingLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Development of thermodynamically stable nanostructured lipid carrier system using central composite design for zero order permeation of econazole nitrate through epidermis.Effects in cigarette smoke stimulated bronchial epithelial cells of a corticosteroid entrapped into nanostructured lipid carriers.Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box-Behnken design approach.Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers.Nanostructured lipid carriers system: recent advances in drug delivery.Advanced systems for glucocorticoids' dermal delivery.Nanostructured lipid carriers and their current application in targeted drug delivery.Topical delivery of paclitaxel for treatment of skin cancer.Nanoparticles: Emerging carriers for drug delivery.Nanostructured Lipid Carriers (NLC)-Based Gel for the Topical Delivery of Aceclofenac: Preparation, Characterization, and In Vivo EvaluationExperimental and molecular modeling approach to optimize suitable polymers for fabrication of stable fluticasone nanoparticles with enhanced dissolution and antimicrobial activity.Nanostructured lipid carriers loaded with simvastatin: effect of PEG/glycerides on characterization, stability, cellular uptake efficiency and in vitro cytotoxicity.Skin targeting of resveratrol utilizing solid lipid nanoparticle-engrossed gel for chemically induced irritant contact dermatitis.Glucosamine derivative modified nanostructured lipid carriers for targeted tumor deliveryLoading of praziquantel in the crystal lattice of solid lipid nanoparticles
P2860
Q28079462-611CD309-F969-4D7D-9666-D06834E8FE4DQ30366990-B5B8F863-885E-4B73-BE2E-8D06866CA806Q34160297-41ADA241-266D-4675-A3E4-E077737289BFQ34768928-7816B8CD-0B34-438E-8D46-D6D25AF8B5E3Q35981175-2A227F10-E603-4A58-849D-1342E900D56CQ36093269-B4306800-2628-4622-BDD0-FFA9FD1A1892Q38038902-40CFAAA1-69C5-43FE-A009-40AC9E0ED8A8Q38094761-AB2C338D-D183-494B-8FFF-4A78445227AAQ38210565-C3E5CB9A-82C9-4C7B-B411-8D07B3F0B151Q40019226-DA35B861-4807-434B-B7D4-0C1DDFF7A7B3Q42009342-1DC5EAF9-0CB6-42F1-991F-6E8FD20B98C1Q42276924-21D2336D-E626-4F74-B43A-C1BAB4CFEA37Q49957833-8CB4DFF6-264B-48A6-8A02-9B225A33BDB8Q52893748-E37C343D-EB7B-4A8F-93F3-FAB12FD8D00DQ53542373-58166EAE-94A8-48C4-A5C5-1E33FDA91891Q57273335-603B0845-9ACB-4800-840B-94E79D38145DQ58494369-16E64BC0-2988-4F94-B38F-A00223C10AB3
P2860
Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC).
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Formulating fluticasone propio ...... ured lipid carriers (PEG-NLC).
@en
Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers
@nl
type
label
Formulating fluticasone propio ...... ured lipid carriers (PEG-NLC).
@en
Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers
@nl
prefLabel
Formulating fluticasone propio ...... ured lipid carriers (PEG-NLC).
@en
Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers
@nl
P50
P1476
Formulating fluticasone propio ...... tured lipid carriers (PEG-NLC)
@en
P2093
Joana Araújo
P304
P356
10.1016/J.COLSURFB.2009.09.033
P577
2009-10-08T00:00:00Z